Union minister of commerce and industry, Piyush Goyal, held a key interaction with stakeholders from India’s pharmaceutical sector, focusing on strengthening industry growth and regulatory reforms. The minister highlighted discussions on innovation, data protection frameworks, investment commitments, and opportunities to scale manufacturing in India.
In a social media post, Goyal said, “Had an engaging interaction with key stakeholders from India’s pharma ecosystem, focusing on strengthening our regulatory frameworks and accelerating growth. Discussed industry perspectives on innovation, data protection frameworks, investment commitments and opportunities to scale manufacturing in India.”He also reiterated the Centre government’s commitment to building a future-ready, innovation-led pharma sector capable of enhancing competitiveness and attracting high-quality investments, while continuing to deliver affordable, world-class healthcare solutions.The meeting comes amid global concerns over potential trade disruptions. In September, US President Donald Trump announced a proposed 100 per cent tariff on branded and patented pharmaceutical products from October 1, 2025, unless manufacturers set up production facilities in the United States. The implementation of the tariff is still pending.Despite these concerns, industry representatives in India remain confident that Indian pharmaceutical exports will largely remain unaffected.Sudarshan Jain, general secretary of the Indian Pharmaceutical Alliance, was quoted by ANI as saying that India primarily exports generic drugs and active pharmaceutical ingredients (APIs) to the US, which are not covered under the proposed tariff.Industry experts note that India’s strong global position in the generics market offers resilience against such policy changes, while the government’s focus on innovation, manufacturing scale, and regulatory efficiency is expected to support long-term growth.The US remains India’s largest pharmaceutical market, accounting for over 31 per cent of total exports and 47 per cent of generic shipments.India’s drug and pharma exports to the US rose to $2.62 billion in September 2025, underlining the sector’s robust performance amid global uncertainties.
